Myosin Therapeutics Inc, a biotechnology company developing innovative therapies for cancer and neurological disorders, announced on Monday that it has been awarded a USD3m grant from the National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH).

This grant is intended to help support the initiation of a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of MT-110, a potential first-in-class treatment option for methamphetamine use disorder (MUD), a severe and growing public health crisis with no FDA approved treatments.

The NIDA grant is part of the Small Business Innovation Research (SBIR) programme, which supports early-stage companies advancing technologies with strong public health potential.

MT-110 was developed through NIH's Blueprint Neurotherapeutics Network, a public-private partnership that helped Myosin Therapeutics' co-founders advance MT-110 from discovery to preclinical development. MT-110 targets a molecular nanomotor protein to reduce the motivation for stimulants and prevent relapses without impacting natural rewards. The company says that preclinical studies have shown excellent safety and efficacy, supporting its advancement into human trials.